221 related articles for article (PubMed ID: 22827973)
21. A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer.
Roché H; De Benedictis E; Cottura E; Govi S; Dalenc F; Locatelli A; Deslandres M; Zambetti M; Gladieff L; Messina M; Gianni L
Clin Breast Cancer; 2012 Jun; 12(3):167-74. PubMed ID: 22607766
[TBL] [Abstract][Full Text] [Related]
22. Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo.
Thangapazham RL; Singh AK; Sharma A; Warren J; Gaddipati JP; Maheshwari RK
Cancer Lett; 2007 Jan; 245(1-2):232-41. PubMed ID: 16519995
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic effect of high-dose green tea extract on weight reduction: A randomized, double-blind, placebo-controlled clinical trial.
Chen IJ; Liu CY; Chiu JP; Hsu CH
Clin Nutr; 2016 Jun; 35(3):592-9. PubMed ID: 26093535
[TBL] [Abstract][Full Text] [Related]
24. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.
Havlin KA; Ramirez MJ; Legler CM; Harris LN; Matulonis UA; Hohneker JA; Hayes DF; Winer EP
Cancer Chemother Pharmacol; 1999; 43(1):68-72. PubMed ID: 9923543
[TBL] [Abstract][Full Text] [Related]
25. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
26. Green tea polyphenol and epigallocatechin gallate induce apoptosis and inhibit invasion in human breast cancer cells.
Thangapazham RL; Passi N; Maheshwari RK
Cancer Biol Ther; 2007 Dec; 6(12):1938-43. PubMed ID: 18059161
[TBL] [Abstract][Full Text] [Related]
27. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.
Coleman R; Finkelstein DM; Barrios C; Martin M; Iwata H; Hegg R; Glaspy J; Periañez AM; Tonkin K; Deleu I; Sohn J; Crown J; Delaloge S; Dai T; Zhou Y; Jandial D; Chan A
Lancet Oncol; 2020 Jan; 21(1):60-72. PubMed ID: 31806543
[TBL] [Abstract][Full Text] [Related]
29. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
Krop IE; Mayer IA; Ganju V; Dickler M; Johnston S; Morales S; Yardley DA; Melichar B; Forero-Torres A; Lee SC; de Boer R; Petrakova K; Vallentin S; Perez EA; Piccart M; Ellis M; Winer E; Gendreau S; Derynck M; Lackner M; Levy G; Qiu J; He J; Schmid P
Lancet Oncol; 2016 Jun; 17(6):811-821. PubMed ID: 27155741
[TBL] [Abstract][Full Text] [Related]
30. Bi-weekly docetaxel in the adjuvant treatment of node-positive or high-risk breast cancer patients: phase I study of the Shiga Breast Cancer Study Group.
Abe H; Ogawa H; Okino T; Kato M; Sako H; Sano H; Shimomatsuya T; Suwa H; Higashide S
Breast Cancer; 2009; 16(1):37-41. PubMed ID: 18493840
[TBL] [Abstract][Full Text] [Related]
31. Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
Blackwell K; Burris H; Gomez P; Lynn Henry N; Isakoff S; Campana F; Gao L; Jiang J; Macé S; Tolaney SM
Breast Cancer Res Treat; 2015 Nov; 154(2):287-97. PubMed ID: 26497877
[TBL] [Abstract][Full Text] [Related]
32. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.
Chao J; Synold TW; Morgan RJ; Kunos C; Longmate J; Lenz HJ; Lim D; Shibata S; Chung V; Stoller RG; Belani CP; Gandara DR; McNamara M; Gitlitz BJ; Lau DH; Ramalingam SS; Davies A; Espinoza-Delgado I; Newman EM; Yen Y
Cancer Chemother Pharmacol; 2012 Mar; 69(3):835-43. PubMed ID: 22105720
[TBL] [Abstract][Full Text] [Related]
33. Phase I/II clinical trial of efficacy and safety of EGCG oxygen nebulization inhalation in the treatment of COVID-19 pneumonia patients with cancer.
Yin X; Zhu W; Tang X; Yang G; Zhao X; Zhao K; Jiang L; Li X; Zhao H; Wang X; Yan Y; Xing L; Yu J; Meng X; Zhao H
BMC Cancer; 2024 Apr; 24(1):486. PubMed ID: 38632501
[TBL] [Abstract][Full Text] [Related]
34. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.
Czito BG; Deming DA; Jameson GS; Mulcahy MF; Vaghefi H; Dudley MW; Holen KD; DeLuca A; Mittapalli RK; Munasinghe W; He L; Zalcberg JR; Ngan SY; Komarnitsky P; Michael M
Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):418-426. PubMed ID: 28497757
[TBL] [Abstract][Full Text] [Related]
35. A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer.
Trudel D; Labbé DP; Araya-Farias M; Doyen A; Bazinet L; Duchesne T; Plante M; Grégoire J; Renaud MC; Bachvarov D; Têtu B; Bairati I
Gynecol Oncol; 2013 Nov; 131(2):357-61. PubMed ID: 23988418
[TBL] [Abstract][Full Text] [Related]
36. Docetaxel-ifosfamide combination in patients with advanced breast cancer failing prior anthracycline-based regimens: results of a phase I-II study.
Kosmas C; Tsavaris N; Mylonakis N; Tsakonas G; Gassiamis A; Skopelitis H; Polyzos A; Malamos N; Karabelis A
J Chemother; 2007 Jun; 19(3):322-31. PubMed ID: 17594929
[TBL] [Abstract][Full Text] [Related]
37. Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer.
Potter DM
Stat Med; 2002 Jul; 21(13):1805-23. PubMed ID: 12111891
[TBL] [Abstract][Full Text] [Related]
38. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins.
Kumar NB; Pow-Sang J; Spiess PE; Park J; Salup R; Williams CR; Parnes H; Schell MJ
Oncotarget; 2016 Oct; 7(43):70794-70802. PubMed ID: 28053292
[TBL] [Abstract][Full Text] [Related]
39. Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer.
Gomez HL; Philco M; Pimentel P; Kiyan M; Monsalvo ML; Conlan MG; Saikali KG; Chen MM; Seroogy JJ; Wolff AA; Escandon RD
Anticancer Drugs; 2012 Mar; 23(3):335-41. PubMed ID: 22123335
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design.
Tevaarwerk A; Wilding G; Eickhoff J; Chappell R; Sidor C; Arnott J; Bailey H; Schelman W; Liu G
Invest New Drugs; 2012 Jun; 30(3):1039-45. PubMed ID: 21225315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
